ALZ-801

← Pipeline

ALZ-801

Alzheon · Alzheimer's disease
Late-stage active active, not recruiting CT.gov grounded

A precision-style Alzheimer's program built around APOE4 biology rather than a broad undifferentiated patient pool.

Open Alzheimer's disease hub Filter main pipeline

Program overview

Mechanism
anti-amyloid oligomer modulation
Modality
small molecule
Phase
Late-stage
Status
active
Recruitment
active, not recruiting
Confidence
medium
Watch priority
2
Last verified
20 Apr 2026

Sponsor and trial identifiers

Sponsor
Alzheon
Trial IDs
NCT06304883, NCT04693520
ClinicalTrials.gov exact matches: NCT06304883, NCT04693520

Regions and recruitment

Active in 5 regions
United States Canada United Kingdom Czechia Netherlands

Indication tags

Alzheimer's APOE4/4

Milestones and catalysts

Last milestone
One of the clearer genetically targeted small-molecule Alzheimer's programs still in serious development.
Next expected catalyst
Long-term extension updates and any signal on APOE4-enriched positioning.

Related pages

Disease hub Alzheimer's disease hub Disease-specific views with programs, mechanisms, and related context.
Research Research agenda Research notes and background around Alzheimer's disease.
Key Targets Key targets The mechanisms and intervention levers behind these programs.
Discover Discover Explainers and visual introductions to the science behind neurodegeneration.
Join Get involved Contribute research, writing, design, engineering, or review.

Related programs

Each card explains why it is here so you can read the overlap at a glance.

Priority 1
Approved / Late-stage active active, not recruiting

Late-stage anti-amyloid program with high strategic importance for the Alzheimer's treatment landscape.

Shown because it shares same disease bench and shared biology: alzheimer's with ALZ-801.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Further rollout, label evolution, and follow-up data.
Last verified
20 Apr 2026

Lecanemab

Eisai / Biogen · Alzheimer's disease
Priority 1
Approved / Late-stage active active, not recruiting

Anti-amyloid antibody program targeting plaque clearance in early Alzheimer's disease.

Shown because it shares same disease bench and shared biology: alzheimer's with ALZ-801.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Additional post-approval data and uptake signals.
Last verified
20 Apr 2026
Priority 2
Mid / Late-stage active active, not recruiting

Follow-on anti-amyloid program that could matter for the next wave of Alzheimer's competition.

Shown because it shares same disease bench and shared biology: alzheimer's with ALZ-801.
Mechanism
anti-amyloid antibody
Modality
monoclonal antibody
Next catalyst
Recruitment updates and larger efficacy or safety read-throughs.
Last verified
20 Apr 2026
Priority 2
Late-stage completed completed

A high-visibility metabolic intervention program that tests whether GLP-1 biology can matter in Alzheimer's disease.

Shown because it shares same disease bench and shared biology: alzheimer's with ALZ-801.
Mechanism
GLP-1 receptor agonism
Modality
small molecule / peptide metabolic therapy
Next catalyst
Interpretation of Phase 3 read-throughs and what they imply for metabolic approaches to AD.
Last verified
20 Apr 2026

Source links

ClinicalTrials.gov NCT06304883 ClinicalTrials.gov NCT04693520 ClinicalTrials.gov search Alzheon pipeline
Scroll to Top